These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35300912)

  • 21. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
    Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
    Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
    Li C; Guo S; Huo J; Gao Y; Yan Y; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():987081. PubMed ID: 36277697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
    Deo SV; McAllister DA; Al-Kindi S; Elgudin Y; Chu D; Pell J; Sattar N
    Diabetes Care; 2022 Dec; 45(12):3054-3057. PubMed ID: 36256925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
    Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
    BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
    Knudsen JS; Baggesen LM; Lajer M; Nurkanovic L; Ustyugova A; Sørensen HT; Thomsen RW
    PLoS One; 2020; 15(3):e0229621. PubMed ID: 32130249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.
    Tang T; Abbott S; le Roux CW; Wilson V; Singhal R; Bellary S; Tahrani AA
    Diabetes Obes Metab; 2018 Mar; 20(3):745-748. PubMed ID: 29053203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.
    Mittman BG; Le P; Payne JY; Ayers G; Rothberg MB
    Curr Med Res Opin; 2024 Mar; 40(3):377-383. PubMed ID: 38193509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
    Sohn M; Nam S; Nauck MA; Lim S
    BMC Med; 2024 Jul; 22(1):273. PubMed ID: 38956548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
    DeRemer CE; Vouri SM; Guo J; Donahoo WT; Winterstein AG; Shao H
    J Diabetes Complications; 2021 Sep; 35(9):107972. PubMed ID: 34247911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
    Patorno E; Pawar A; Bessette LG; Kim DH; Dave C; Glynn RJ; Munshi MN; Schneeweiss S; Wexler DJ; Kim SC
    Diabetes Care; 2021 Mar; 44(3):826-835. PubMed ID: 33495295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?
    Barth SD; Kostev K; Krensel M; Mathey E; Rathmann W
    Exp Clin Endocrinol Diabetes; 2023 Mar; 131(3):153-161. PubMed ID: 35981560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.
    Luo J; Gabriel N; Korytkowski M; Hernandez I; Gellad WF
    Diabetes Res Clin Pract; 2022 May; 187():109855. PubMed ID: 35346753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
    Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.
    Kim HS; Yoon T; Jung CH; Park JY; Lee WJ
    Diabetes Metab J; 2022 Jul; 46(4):658-662. PubMed ID: 34743486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.